Regeneron Pharma Expects Q4 Results To Include $24 Mln In Acquired In-process R&D Charge
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) said Monday it currently expects that its financial results for the second quarter 2024 will include an acquired in-process research and development charge of approximately $24 million on a pre-tax basis.
This charge relates to up-front payments, as well as a premium on equity securities purchased, in connection with collaboration and licensing agreements.
This charge is expected to negatively impact each of GAAP and non-GAAP net income per share for the second quarter 2024 by approximately $0.18.
read more
Regeneron Pharma Q2 Results Top Estimates - Update
Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) reported on Thursday that net income for the second quarter increased to $1.43 billion or $12.41 per share from $968 million or $8.50 per share in the prior-year quarter.
RTTNews
|
Pred 195 dňami
Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU
Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
RTTNews
|
Pred 229 dňami
Regeneron Pharma Q4 Results Top Estimates - Update
Regeneron Pharmaceuticals, Inc. (REGN) reported on Friday that net income for the fourth quarter declined 3 percent to $1.16 billion or $10.19 per share from $1.20 billion or $10.50 per share in the prior-year quarter.
RTTNews
|
Pred 376 dňami
Regeneron Completes Acquiring Sanofi's Stake In Libtayo
Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
RTTNews
|
Pred 957 dňami
U.S. Consumer Prices Climb 0.5% In January, More Than Expected
Consumer prices in the U.S. increased by more than expected in the month of January, according to a report released by the Labor Department on Wednesday. The Labor Department said its consumer price index advanced by 0.5 percent in January after climbing by 0.4 percent in December. Economists had expected consumer prices to rise by 0.3 percent.
RTTNews
|
Pred 7 h 14 min
Heineken Stock Climbs On Positive Outlook, Share Buyback, Despite Weak FY24 Results
Shares of Heineken N.V. were gaining around 13 percent in the Amsterdam trading after the Dutch brewer announced positive outlook for fiscal 2025, a dividend, and up to 1.5 billion euros share buyback program. This was despite reporting weak profit and revenues in its fiscal 2024.
RTTNews
|
Pred 7 h 54 min
U.S. Consumer Prices Climb More Than Expected In January
Consumer prices in the U.S. increased by more than expected in the month of January, according to a report released by the Labor Department on Wednesday.
RTTNews
|
Pred 8 h 19 min
India Inflation Weakens More Than Forecast To Lowest Level In 5 Months
India's consumer price inflation slowed more than expected to a five-month low in January reinforcing expectations that the Reserve Bank of India will reduce interest rates further. The consumer price index registered an increase of 4.31 percent on a yearly basis in January, weaker than the 5.22 percent rise logged in December, official data revealed on Wednesday.
RTTNews
|
Pred 9 h 29 min
